NORTHBROOK, Ill., June 22, 2014 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., a men’s health specialty pharmaceutical company focused on the development and commercialization of REXTORO ( (Testosterone Undecanoate), an oral testosterone (T) replacement product, today presented Phase 3 clinical data from two studies that support the safety and efficacy of REXTORO for T-replacement therapy in men with hypogonadism. These results are being presented from 1-3 p.m. CT today at the 16th International Congress of Endocrinology and The Endocrine Society’s 96th Annual Meeting and Expo (ICE/ENDO 2014) in Chicago during the clinical poster session, “Male Reproduction: Hypogonadism and Reproductive Aging.”
Help employers find you! Check out all the jobs and post your resume.
